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Abstract
Sera from patients with insulin-dependent diabetes immu-
noprecipitate 64,000-Mr proteins, distinct from glutamate
decarboxylase, that are cleaved to 37,000- and 40,000-Mr
fragments by trypsin. We investigated possible relationships
between 37,000- or 40,000-Mr fragments of antigen and the
tyrosine phosphatase-like protein, IA-2 (ICA512). Anti-
bodies from nondiabetic relatives bound differentially to
37,000- and 40,000-Mr fragments indicating presence of dis-
tinct epitopes. Precursors of these fragments could be sepa-
rated on immobilized lectins, suggesting different carbohy-
drate content. Levels of antibodies to 40,000-Mr fragments
were strongly associated with those to the intracellular do-
main of LA-2. Recombinant intracellular domain of UI-2
blocked binding of antibodies to 40,000-Mr fragments ex-
pressed by insulinoma cells and partially blocked binding
to 37,000-Mr fragments. Furthermore, trypsinization of re-
combinant intracellular domain of UI-2 generated proteo-
lytic fragments of identical Mr to the 40,000-Mr fragments
of insulinoma antigen; 37,000-Mr fragments were not gener-
ated. Thus, 40,000-Mr fragments of islet autoantigen are
derived from a protein similar or identical to the tyrosine
phosphatase-like molecule, UI-2. The 37,000-Mr fragments
are derived from a different, although related, protein. (J.
Clin. Invest. 1995. 1506-1511.) Key words: insulin-depen-
dent diabetes * autoantigens * autoantibodies * protein tyro-
sine phosphatase - glycoproteins
Introduction
Patients with insulin-dependent diabetes mellitus (IDDM) ' pos-
sess antibodies to multiple islet cell antigens including insulin,
the 65-kD isoform of glutamate decarboxylase (GAD), and
carboxypeptidase H ( 1). In our laboratory we have been charac-
terizing protein autoantigens in IDDM that are detected on SDS-
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40,000-Mr proteolytic fragments; GAD, glutamate decarboxylase; IA-
2ic, intracellular domain of IA-2; ICA, islet cell antibody; IDDM, insu-
lin-dependent (type 1) diabetes mellitus.
PAGE as diffuse 64,000-Mr bands but cleaved by trypsin to
37,000- and 40,000-M, proteolytic fragments (37k and 40k anti-
gens) (2). Antibodies to these antigens are found in up to 80%
of recent onset IDDM patients and are very closely associated
with diabetes development in identical twins (3) and first-de-
gree relatives of IDDM patients (4), in patients with polyendo-
crine autoimmunity or stiff-man syndrome (5), and in islet cell
antibody (ICA)-positive schoolchildren (6). These antibodies
should be particularly useful in identifying individuals at risk
for IDDM who might be candidates for disease prevention pro-
tocols.
Identification of the 37k and 40k antigens is essential for
the development of better assays for antibodies to the proteins
for screening purposes and to assess the role of the antigens in
disease pathogenesis. The antigens are expressed at low levels
in pancreatic islets and insulinoma cells, and our attempts to
purify sufficient quantities of protein for amino acid sequencing
or antibody production have not been successful. As an alterna-
tive approach, we have compared the physical and antigenic
properties of the proteins with potential autoantigens identified
in other studies. We now report that the 37,000- and 40,000-
Mr fragments are derived from different, but probably related,
protein precursors. Furthermore, we demonstrate that the
40,000-Mr fragments are related to a protein designated IA-2
(7), which is homologous to members of the receptor-linked
family of protein tyrosine phosphatases and which shares se-
quence identity with a cloned target for antibodies in human
IDDM, ICA512 (8).
Methods
Sera. Sera from recent onset IDDM patients, from first-degree relatives
of IDDM patients, and from healthy controls, previously characterized
for antibodies to islet 64,000-Mr proteins, to GAD, and to tryptic frag-
ments of islet antigen were selected from previous studies on autoanti-
gens in IDDM (3, 9-11).
Islets and cell lines. Islets were isolated from 5-7-day-old newborn
Wistar rats as described (12). The rat insulinoma cell line subclone
RIN-5AH (13) was maintained in tissue culture in RPMI 1640 medium
(GIBCO BRL, Paisley, UK) containing 10% FCS (Sigma Chemical
Co., Poole, Dorset, UK). Endogenous proteins in islets and insulinoma
cells were labeled with [35S] methionine (Amersham International, Little
Chalfont, UK) as described (9).
cDNA cloning and expression. RNA was extracted from human fetal
brain (gift of Dr. Kate Langford, King's College School of Medicine and
Dentistry, London) using Tri reagents (Molecular Research Center,
Inc., Cincinnati, OH). First-strand cDNA was synthesized with Moloney
murine leukemia virus reverse transcriptase (GIBCO BRL) using poly-
A and random primers. Human islet cDNA was a gift of Dr. Paul Banga
(King's College School of Medicine and Dentistry, London). A segment
of ICA512 DNA sequence was amplified from human fetal brain cDNA
with Taq DNA polymerase using primer sequences: 5 '-ATGAACCGG-
GCAGAGGGTCCA-3' and 5 '-TCATCAATCTCCTTCACTCCT-3'.
Amplification products were reamplified with the same primer sequences
but with additional sequences added at 5' ends corresponding to restric-
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tion sites for BamHI and EcoRI, respectively. Reamplification products
were ligated into the BamHI and EcoRI sites of the vector pGEM 4Z
(Promega Corp., Madison, WI). DNA sequence corresponding to the
intracellular domain of IA-2 (IA-2ic) was amplified from human islet
cDNA using the primer sequences: 5 '-ATGCAGCAAGACAAGGAG-
CGCCTG-3' and 5'-TCACTGGGGCAGGGCCTTGAG-3'. Amplifi-
cation products were cloned directly into the vector pGEM-T (Promega)
and subcloned into pGEM 4Z and PinPointlm (Promega).
A 3.5-kb cDNA containing the coding region for the rat homologue
of the IA-2 molecule was obtained by screening a rat brain cDNA
library in X-ZAP (Stratagene Ltd., Cambridge, UK) with the human
ICA512 DNA segment. The cDNA was subcloned into pGEM 1 lZ
(Promega). A 5.3-kb cDNA for the 65-kD isoform of rat GAD was
also cloned from the rat brain library by screening with a 346-bp rat
GAD65 DNA segment generated by DNA amplification. The coding
region for rat GAD65 was amplified from the 5.3-kb cDNA using specific
primers and cloned into pGEM 4Z.
Nucleotide sequences of cloned products were verified by automated
sequencing using a sequencer (ABI 373A; Applied Biosystems Inc.,
Foster City, CA). ICA512, IA-2ic, and GAD sequences in pGEM 4Z
or pGEM 1 1Z were transcribed and translated in vitro in the presence
of [351 ]methionine (Amersham) using the TNTh-coupled reticulocyte
lysate system (Promega). IA-2ic was also expressed in Escherichia coli
as a fusion protein with a biotin-labeled peptide sequence at the NH2
terminus using the PinPoint' expression system. Bacteria were lysed
by stirring with lysozyme (1 mg/ml) in 150 mM NaCl, 10 mM Hepes,
pH 7.4, followed by addition of Triton X-100 (0.1% vol/vol) for 5 min
and DNase (20 U/ml) for 5 min. Particulate material was sedimented
by centrifugation at 10,000 g for 15 min. The expressed fusion protein
was purified from lysates by affinity chromatography on streptavidin-
polymethacrylate (Soft LinkTm, Promega) columns. Protein was eluted
with 5 mM biotin, which was subsequently removed by dialysis against
1 mM sodium phosphate, pH 7.4. The purified IA-2ic fusion protein
resolved on SDS-PAGE as a single Coomassie brilliant blue-stained
band with an Mr of 59,000.
Immunoprecipitation. Radiolabeled islets or insulinoma cells were
extracted in Triton X-1 14 and subject to detergent-phase separation as
previously described (2). Rat IA-2, human IA-2ic, or rat GAD65 cDNA
in pGEM-4Z, and cDNA for human GAD65 in the vector pB1882 (gift
of Dr. Thomas Dyrberg, Novo Nordisk, Copenhagen, Denmark) were
transcribed and translated in vitro using commercial kits (Promega) in
the presence of [35S] methionine (Amersham). Incorporated radioactiv-
ity was determined by precipitation with 10% TCA and scintillation
counting. Aliquots (20 p1) containing 5 x 106 cpm of radiolabeled
protein in cell extracts or 20,000 cpm of in vitro translated protein were
incubated in immunoprecipitation buffer (10 mM Hepes, pH7.4, 150
mM NaCl, 0.5% Triton X-100, 0.5 mg/ml BSA, 10 mM benzamidine,
and 5 mM methionine) with 5 y1L of test serum for 5 h at 4°C. In some
experiments, purified IA-2ic fusion protein was added before addition
of serum. Immune complexes were isolated on 5 ll of protein A-
Sepharose and immunoprecipitates washed five times with 500 Jsl of
immunoprecipitation buffer and once with 500 j1 of water. Immune
complexes were analyzed by SDS-PAGE and autoradiography. In some
experiments with in vitro translated proteins, immunoprecipitates were
resuspended in 500 [61 of water, and radioactivity in 200-[lI aliquots
was determined by liquid scintillation counting. Radioactivity in immu-
noprecipitates was expressed as a percentage of that precipitated by a
positive control serum included in each experiment.
Lectin affinity chromatography. Triton X-1 14 detergent phase-puri-
fied extracts of [35S ] methionine-labeled RIN-5AH cells were incubated
with 50 pl of the lectins immobilized on Sepharose or agarose at 4°C for
30 min and subsequently washed three times with immunoprecipitation
buffer. Bound proteins were eluted three times with 50 1l of 0.5 M
a-methyl mannoside (lentil lectin, concanavalin A), 0.5 M N-acetyl
glucosamine (wheat germ agglutinin), 0.5 M N-acetyl galactosamine
(soybean agglutinin), or 0.5 M N-acetyl neuraminic acid (slug aggluti-
nin). Eluates were subjected to immunoprecipitation with sera positive
and negative for antibodies to 37k antigen as described above.
Database searches. Searches of the GenBank DNA sequence data-
base and DNA sequence analyses were performed with the University
of Wisconsin Genetics Computer Group programs (14).
Statistical analysis. The degree of correlation among antibody mea-
surements on serum samples was determined by linear regression anal-
ysis.
Results
Binding of antibodies from relatives of IDDM patients to
37,000- and 40,000-Mr fragments of antigen. We have pre-
viously reported a strong correlation between the presence of
antibodies to 37,000- and 40,000Mr fragments of antigen in
sera from IDDM patients ( 15 ). These results suggested that the
proteolytic fragments have similar antigenic properties and may
be derived from the same or related proteins. However, analysis
of binding of antibodies in sera of nondiabetic relatives of
IDDM patients has revealed differences in antibody reactivity
to the two fragments. Thus, in addition to sera that contain
antibodies to both 37,000- and 40,000-Mr fragments, sera were
identified that contain antibodies only to the 40,000-Mr frag-
ments (Fig. 1 A). These results suggest that there may be differ-
ences in the antigenic properties of these antigenic fragments
and that they may not necessarily be derived from the same
protein.
Binding ofprecursors to the 37,000- and 40,000-Mr frag-
ments to lectins. Further evidence that the 37,000- and 40,000-
Mr fragments are not derived from the same protein was ob-
tained by analysis of binding of antigen to immobilized lectins.
Solubilized extracts of [35S ] methionine-labeled RIN-5AH insu-
linoma cells were applied to different immobilized lectins,
bound proteins eluted with appropriate sugars, and eluates ana-
lyzed for the presence of autoantigens by immunoprecipitation
and trypsin treatment. Precursors to 40,000-Mr fragments were
recovered in eluates of wheat germ agglutinin columns (speci-
ficity N-acetyl glucosamine) whereas those of 37,000Mr frag-
ments were absent (Table I). Precursors of 37,000-M, frag-
ments were recovered in eluates of lentil lectin columns (see
Table I, mannose specificity). These results demonstrate that
these autoantigens are glycoproteins and that the precursors to
the 37,000- and 40,000-Mr fragments have different carbohy-
drate content.
Correlation ofantibodies to 40,000-Mrfragments with anti-
bodies to ICA512 and IA-2. Screening of islet cDNA libraries
with sera from IDDM patients has recovered cDNA for a num-
ber of potential IDDM-associated autoantigens, including a
clone designated ICA512, that contains a domain homologous
to protein tyrosine phosphatases (8). Analysis of the predicted
amino acid sequence of this protein revealed a number of simi-
larities with the 37k and 40k antigens, including a predicted
molecular mass of - 60 kD, the presence of potential N-glyco-
sylation sites, and a putative transmembrane domain, consistent
with the known amphiphilic properties of the 37k- and 40k-
antigens (2). A segment of cDNA containing the reported anti-
body binding site on ICA512 (Fig. 2) was obtained by DNA
amplification from human fetal brain cDNA and cloned into the
vector pGEM 4Z. Protein labeled with [355]methionine was
generated by in vitro transcription and translation and immuno-
precipitated with sera of known reactivity with 37,000- and
40,000-Mr antigenic fragments. Sera from IDDM patients and
relatives, but not healthy controls, were found to immunoprecip-
itate the in vitro translated protein (Fig. 1 B). All sera that
immunoprecipitated the protein were found to be positive for
antibodies to 40,000Mr fragments of islet autoantigen. How-
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a b c d e f g h i j k I mn o p q r s t u v w Figure 1. Immunoprecipitation of insu-
linoma cell or recombinant antigens by
A 37/40k-antigens - 40k antibodies in sera of relatives of IDDM
~-_37k patients. (A) Sera from 23 nondiabetic,
ICA-positive relatives (a-w) of IDDM
patients were used to immunoprecipitate
B ICA-512 0 w } :;: : proteins from Triton X- 14 extracts of
[35S] methionine-labeled RIN cells. Im-
mune complexes were isolated on protein
XIA2ic!A-Sepharose and treated with trypsin
(0.1 mg/ml) before SDS-PAGE and au-
toradiography. Antigens were detected as
D GAD-65 40,000-M fragments (upper bands in A,
lanes d, e, i, 1, p, r, t, and w) or 37,000-
Mr bands (lower bands in A, lanes d, t,
and w). The same sera were used to immunoprecipitate in vitro transcribed and translated proteins representing the reported ICA512-1 sequence
(B), IA-2ic (C), or human GAD-65 (D). Immunoprecipitated proteins were resolved on SDS-PAGE and visualized by autoradiography.
ever, not all sera positive for the antibodies to the islet antigen
immunoprecipitated the translated product (compare Fig. 1, A
and B). The ICA512 segment cloned by us is therefore not
fully homologous to the islet 37k or 40k antigens.
A search of the GenBank database identified an additional
cDNA sequence, IA-2/PTP, containing the complete ICA512
sequence but with extended sequence at the 5' end and an
additional guanosine nucleotide within the coding region. The
consequent frame-shift resulted in a longer than predicted pro-
tein sequence COOH-terminal to the tyrosine phosphatase do-
main, and the entire IA-2 sequence encodes a protein of a pre-
dicted molecular mass of 106 kD (7). A segment of human
IA-2 cDNA representing the coding region 3' to the putative
transmembrane domain (IA-2ic) was obtained by DNA ampli-
fication of human islet cDNA and cloned into pGEM 4Z. A
cDNA clone including the coding region for the rat homologue
of the complete IA-2 molecule was obtained from a rat brain
library, and the cDNA was subcloned into pGEM 4Z. The corre-
sponding [35S] methionine-labeled proteins were transcribed
and translated in vitro. The dominant translation products were
of appropriate size (42,000 and 105,000 Mr for IA-2ic and the
complete rat IA-2 molecule, respectively) but minor products
of smaller sizes were also detected which are probably the
results of translation from intramolecular methionine codons.
Reactivity with antibodies in sera from IDDM patients and
relatives was determined. Virtually all sera positive for antibod-
ies to 40,000-M, fragments recognized the IA-2ic product, in-
Table L Binding of 37,000- and 40,000Mr Fragments ofAntigen
to Lectins
37k 40k
Lectin Specificity fragments fragments
Lentil lectin Mannose +
Concanavalin A Mannose - -
Wheat germ agglutinin N-acetyl glucosamine - ++
Soybean agglutinin N-acetyl galactosanmine -
Slug agglutinin N-acetyl neuraminic acid -
Lectins immobilized on Sepharose or agarose were incubated with detergent
extracts of RIN-5AH insulinoma cells for 30 min, washed, and bound glycopro-
teins eluted with appropriate sugars. The presence of precursors to 37,000- (37k)
and 40,000-M, (40k) fragments was determined by immunoprecipitation with a
strongly antibody-positive serum followed by analysis of trypsinized immune
complexes by SDS-PAGE and autoradiography. Bands immunoprecipitated were
scored as positive (+) or strongly positive (++).
cluding sera negative for antibodies to the 37,000Mr fragment
(Fig. 1 C). Similar results were obtained for the complete rat
IA-2 molecule. Furthermore, a strong correlation between levels
of antibodies to IA-2ic and the 40,000-Mr fragments was ob-
served (r = 0.85; P . 0.001; Fig. 3). No association between
antibodies to IA-2ic and antibodies to GAD was detected (Fig.
1 D). These results demonstrate that the 40,000-Mr fragments
share similar antigenic properties with the putative cytoplasmic
domain of IA-2.
Sera containing antibodies to IA-2ic immunoprecipitate
64,000-Mr protein from islet extracts. We have previously
shown that the 37,000- and 40,000-Mr fragments are derived
from proteins that are resolved as diffuse bands of Mr 64,000 on
SDS-PAGE and that are distinct from GAD (2). We therefore
investigated whether the presence of antibodies to IA-2ic in
recent onset diabetic patients' sera was associated with the abil-
ity to immunoprecipitate 64,000-Mr proteins from islet extracts.
Sera were also tested for the presence of antibodies to GAD.
Antibodies in sera from IDDM patients immunoprecipitated
64,000-Mr proteins that were resolved as both sharp and diffuse
bands on SDS-PAGE (Fig. 4 A); diffuse 64,000-Mr bands were
detected in patients with high levels of antibodies to IA-2ic
(Fig. 4 A, lanes 1, 5, 7, and 9) whereas sharp 64,000-Mr bands
were associated with the presence of high levels of GAD anti-
bodies (e.g., Fig. 4 A, lanes 4, 11, and 13). No protein bands
of different Mr were consistently and specifically detected in
immunoprecipitates with sera positive for these antibodies.
Blocking of binding of antibodies to 37,000- and 40,000-
Mr fragments of autoantigen by IA-2ic. To further investigate
the relationship of IA-2 to 37k- and 40k-antigens, the IA-2ic
1 980
t. U.s-I ~ -l.k: i ;,
SP
IA-2 sequence
TM PTP
643 960
:77:: KICA-512
603 980L.~ IA-2 ic
Figure 2. Location of cloned cDNA sequences within IA-2 sequence.
Schematic representation of IA-2 sequence is shown. The shaded regions
indicate locations of a putative signal peptide (SP), transmembrane
domain (TM), and protein tyrosine phosphatase homology region
(PTP). Two sequences were isolated by DNA amplification, one repre-
senting the ICA5 12 sequence containing autoantibody binding sites (res-
idues 643-960) the other representing the entire intracellular domain
of the protein (residues 603-980). cDNA for the complete IA-2 mole-
cule was recovered from a rat brain cDNA library.
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Figure 3. Association of antibodies to IA-2ic with antibodies to 40,000-
Mr fragments of islet autoantigen. Levels of antibodies to 40,000-Mr
fragments of islet antigen determined in previous studies were compared
with levels of antibodies to IA-2ic in sera from 28 recent onset IDDM
patients and nine first-degree relatives of IDDM patients. A strong asso-
ciation (r = 0.85; P ! 0.001) was detected between these two antibody
specificities.
A knmunoprec4*med Met protelm
64k-o
B Antibodies to IA-2 Ic
o Pr'7 - M VZZW#A V-A2 - WA.I2 VIA.-anI-AM)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 4. Antibodies to antigens in IDDM patients. (A) Autoradiogram
showing proteins immunoprecipitated from Triton X-1 14 extracts of
[35S ]methionine-labeled rat islets by sera from 16 recent onset IDDM
patients. The arrow marks the position of the 64,O00-Mr bands. Recom-
binant IA-2ic (B) and recombinant human GAD-65 (C), both expressed
by in vitro transcription and translation, were immunoprecipitated by
the same sera. Radiolabeled protein immunoprecipitated was determined
by scintillation counting and expressed as a percentage of that precipi-
tated by a positive control serum.
_4 -_
40k
-- 37k
*U-|| 42k
C IA-2
IA-21c: -+ - + - +
D GAD-65
.- 105k
IA-2ic:
- 65k
Figure 5. Blocking of binding of antibodies to antigens by IA-2ic. (A)
Triton X-1 14 detergent extracts of RIN insulinoma cells were incubated
with serum from four IDDM patients positive for antibodies to islet
37k-antigen with buffer only (left lane for each serum) or with buffer
containing purified IA-2ic fusion protein (right lane for each serum).
Autoradiograms showing proteins immunoprecipitated are illustrated.
Sera from IDDM patients were also analyzed for ability of IA-2ic to
block binding to human IA-2ic (B), rat IA-2 protein (C), and rat GAD65
(D) expressed by in vitro transcription and translation. The Mr's of the
major radiolabeled proteins immunoprecipitated are marked.
cDNA was subcloned into the PinPoint'" expression vector and
expressed as a biotin-labeled fusion protein in E. coli. Expres-
sion of recombinant protein of appropriate size and antigenicity
was confirmed by immunoprecipitation with sera from IDDM
patients, followed by Western blotting and detection with alka-
line phosphatase-conjugated streptavidin (data not shown).
The ability of unlabeled recombinant IA-2ic to block binding
to [35S]methionine-labeled 37,000- and 40,000-Mr fragments
of RIN cell antigen was determined. Addition of purified IA-
2ic fusion protein blocked binding to both 37,000- and 40,000-
M, fragments of antigen, although with some sera blocking of
binding to 37,000-Mr fragments was incomplete (Fig. 5 A).
The IA-2ic preparation also blocked autoantibody binding to
human IA-2ic (Fig. 5 B) and to the complete rat IA-2 molecule
(Fig. 5 C) expressed by in vitro transcription and translation
but had no effect on binding to GAD65 (Fig. 5 D). These results
further confirm the similar antigenic properties of IA-2 and the
40k-antigen.
Trypsinization of IA-2 generates 40,000-Mr fragments. Ex-
periments were performed to determine whether trypsin treat-
ment of IA-2 generates proteolytic fragments of similar size to
those of native 37k- or 40k-antigen. Radiolabeled human IA-
2ic and the complete rat IA-2 molecule were obtained by in vitro
transcription and translation. Translated proteins were incubated
with sera from IDDM patients and immunoprecipitated proteins
either run directly on SDS-PAGE or treated with trypsin (0.1
mg/ml) for 20 min on ice before gel electrophoresis. The mobil-
ity on SDS-PAGE of the proteolyzed immunoprecipitates was
compared with that of similarly treated immunoprecipitates with
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la-21c IA-2
Trypsin: -
I"
Islet
antigen
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G- 37k
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Figure 6. Trypsinization of immunoprecipitated IA-2 and islet antigen.
IA-2ic (left panel) and the complete rat IA-2 protein (center panel)
were expressed by transcription and translation in vitro and subjected
to immunoprecipitation with IDDM patients' sera. Immunoprecipitates
were analyzed directly by SDS-PAGE for proteins precipitated or treated
with trypsin (0.1 mg/ml) for 20 min on ice before SDS-PAGE as
indicated on the figure. The mobilities of bands detected were compared
with those seen in trypsinized immunoprecipitates performed with Triton
X-1 14 extracts of [35S ] methionine-labeled rat islets (right panel). The
Mr's of the major protein bands detected are marked.
RIN cells as source of 37k-antigen. Trypsin cleavage of both
IA-2ic and the complete IA-2 protein generated a major frag-
ment with identical mobility to the 40,000-M, fragment of insu-
linoma antigen (Fig. 6). Fragments of 37,000 Mr were not
generated under these conditions.
Discussion
A protein containing a domain homologous to the receptor-
linked family of protein tyrosine phosphatases was first shown
to be recognized by antibodies in IDDM by Rabin et al. (8).
A clone (ICA512-1) encoding a portion (predicted molecular
mass 33 kD) of the protein encompassing the tyrosine phospha-
tase domain was recovered from a human islet cDNA library
by screening with antibodies from IDDM patients (16). The
expressed protein was subsequently shown to be recognized by
antibodies in sera of 48% of newly diagnosed IDDM patients
by ELISA. Rescreening of the cDNA library identified a longer
clone (ICA512-3) encoding a 60-kD protein, including a puta-
tive transmembrane domain and two potential N-glycosylation
sites (8). Lan and colleagues (7) independently isolated a
cDNA (IA-2) containing sequence virtually identical to ICA512
but extended at the 5' end, with a 3-kb open reading frame
encoding a protein of predicted molecular mass of 106 kD.
Neither group was able to demonstrate tyrosine phosphatase
enzyme activity of the expressed protein using a variety of
substrates. Furthermore, amino acid substitutions are present in
IA-2 at highly conserved residues in other tyrosine phosphatases
that have been shown to abolish enzyme activity towards syn-
thetic substrates (17). Whether IA-2 (ICA512) has a very re-
stricted substrate specificity or whether it is inactive as a tyro-
sine phosphatase remains to be determined.
In our initial studies on antibody binding to IA-2 and
ICA512 we used protein expressed by a cloned cDNA encoding
the reported protein sequence of ICA512-1, a region of the
molecule known to contain the antibody binding domain (8).
However, owing to a probable error in the ICA512 sequence,
this protein has a COOH terminus truncated by 20 amino acid
residues. We subsequently cloned the entire intracellular do-
main of IA-2, encoding a protein fragment (IA-2ic) 60 amino
acids longer than our ICA512 product. Virtually all sera positive
for antibodies to 40,000Mr fragments bound to IA-2ic, and a
strong correlation between antibody levels was detected. Ap-
proximately 50% of sera positive for antibodies to IA-2ic also
bound the shorter ICA5 12 polypeptide, showing that this region
contains epitopes for some, but not all, of these diabetes-associ-
ated antibodies and revealing heterogeneity between patients in
the epitopes recognized.
The strong correlation between antibodies to IA-2ic and
the 40,000Mr fragments indicate that these are antigenically
similar. Other observations provide further evidence that these
proteins are related. Thus, unlabeled IA-2ic blocked binding of
antibodies to the 40,000-Mr antigenic fragment, and trypsiniza-
tion of immunoprecipitated IA-2 and the cytoplasmic domain
generated a polypeptide of identical M, to these fragments. Sera
containing high levels of antibodies to IA-2ic were shown to
immunoprecipitate a protein migrating as a diffuse 64,000-Mr
band on SDS-PAGE, as previously observed for precursors to
the 40,000-M, fragments (2). The predicted protein sequence
has a putative transmembrane domain and potential N-glycosyl-
ation site; this is consistent with the known properties of the
37k- and 40k-antigens (2, 7). Together, these data suggest that
the 40,000-M, fragments are derived from a protein similar or
identical to IA-2. Sera containing antibodies to 40k-antigen
were able to immunoprecipitate the complete 105,000-M, rat
brain IA-2 protein expressed by in vitro transcription and trans-
lation. However, addition of excess cytoplasmic domain of the
protein completely blocked autoantibody binding to the full-
length molecule, suggesting that autoantibody recognition is
restricted to the intracellular domain of the enzyme.
The predicted molecular mass of IA-2 (106 kD, including
a putative signal peptide) is higher than that expected of the
precursor to the 40,000-Mr fragments, which migrates on SDS-
PAGE with an M, of - 64,000 (Fig. 4 and reference 2). Only
64,000- and 38,000-Mr proteins have been detected by immuno-
precipitation from non-protease-treated extracts of islets with
diabetes-associated antibodies (18, 19). The Mr of native IA-2
has not been reported, so comparison of molecular weights must
await further characterization of the natural protein. However,
there are a number of possible reasons for the discrepancy. It
is possible that the diffuse 64,000-Mr bands detected in immu-
noprecipitates with sera containing antibodies to 40k antigen are
themselves degradation products of a higher molecular weight
protein, although precautions were taken to inhibit proteolytic
cleavage during cell extraction and immunoprecipitation. IA-2
molecule may be subject to proteolytic processing in vivo, or
posttranslational modifications, such as glycosylation, may
yield a protein that migrates at a lower than expected Mr. Alter-
natively, a different translation start site to that predicted may
be used. Members of the protein phosphatase family are also
known to be subject to alternative splicing to yield different
isoforms (20-22), but whether this is a feature of IA-2-related
phosphatases is not known. Clearly, amino acid sequence data
on the precursor to 40,000-Mr fragments are required to define
the precise relationship of this antigen to IA-2.
We have previously shown that antibodies in IDDM pa-
tients' sera to 37,000Mr fragments are strongly correlated with
those to 40,000-Mr fragments (15), suggesting that these are
antigenically similar. However, data presented here identify an-
tibodies in sera from nondiabetic relatives that can distinguish
between the two fragments (Fig. 1 A). The precursors can also
be separated by binding to immobilized lectins, indicating that
these have different carbohydrate contents. Trypsinization of
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IA-2ic or the complete IA-2 protein did not generate 37,000-
Mr fragments. However, recombinant IA-2ic was able to block
autoantibody binding to 37,000-M fragments, although with
some sera blocking was incomplete. These observations indicate
that the 37,000-Mr fragments are unlikely to be derived from
IA-2, although the ability of IA-2ic to block autoantibody bind-
ing to the fragments does suggest that the antigen is structurally
similar to another member of the protein tyrosine phosphatase
family.
A number of potential islet cell antigens have been identified
by screening of islet cDNA libraries with IDDM patients' sera,
including carboxypeptidase H and ICA 69 (23, 24). However,
to date, these have not corresponded to antigens detected by
analysis of antibody reactivity with proteins in islet extracts,
and the expressed recombinant proteins do not always show
reactivity with patients' sera in immunoprecipitation reactions
(25). Neither GAD nor insulin have been identified by the
library screening approach. Diabetes-associated antibodies to
these antigens are known to bind epitopes that are highly depen-
dent on protein conformation (26, 27), and these may not be
displayed by the library. If the 40,000-M, fragments of islet
antigen are indeed equivalent to IA-2 and ICA512, then this
protein will represent a rare case of an islet antigen identified
by both immunochemical and molecular biological approaches.
We have shown in different populations that antibodies to the
37k and 40k antigens are very closely associated with diabetes
development (3-6). The finding that the 40,000-M, fragments
of this antigen are related to the cloned proteins IA-2 and
ICA5 12 will simplify assessment of the predictive value of these
antibodies in larger populations. Furthermore, the availability of
suitable amounts of recombinant antigen will allow studies to
define the role of the protein in pathogenesis of disease and in
its potential use in disease prevention therapies.
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